

- Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction.** Berger, A. K., S. Duval, et al. J Am Coll Cardiol (2003).**42**(2): 201-8
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12875751
- Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study.** Borghi, C. and E. Ambrosioni. Am Heart J (2003).**145**(1): 80-7
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12514658
- Relation of inflammation and benefit of statins after percutaneous coronary interventions.** Chan, A. W., D. L. Bhatt, et al. Circulation (2003).**107**(13): 1750-6
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12665489
- Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction.** Correia, L. C., A. C. Sposito, et al. Am J Cardiol (2003).**92**(3): 298-301
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12888137
- Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.** Granger, C. B., K. W. Mahaffey, et al. Circulation (2003).**108**(10): 1184-90
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12925454
- Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction.** Harjai, K. J., G. W. Stone, et al. Am J Cardiol (2003).**91**(6): 655-60
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12633793
- Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease.** Horne, B. D., J. B. Muhlestein, et al. Circulation (2003).**107**(2): 258-63
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12538425
- Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women.** Hu, F. B., E. Cho, et al. Circulation (2003).**107**(14): 1852-7
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12668520
- Beta-blockers reduce the incidence of clinical restenosis: prospective study**

of 4840 patients undergoing percutaneous coronary revascularization.

Jackson, J. D., J. B. Muhlestein, et al. Am Heart J (2003).**145**(5): 875-81

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12766747

Effects of amlodipine on ischemia after percutaneous transluminal coronary angioplasty: secondary results of the Coronary Angioplasty Amlodipine Restenosis (CAPARES) Study. Jorgensen, B. and E. Thaulow. Am Heart J (2003).**145**(6): 1030-5

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12796759

Adjunctive pharmacotherapy before percutaneous coronary intervention in non-ST-elevation acute coronary syndromes: the role of modulating inflammation. Kereiakes, D. J. Circulation (2003).**108**(16 Suppl 1): III22-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14605016

Effects of glucose-insulin-potassium infusion on chronic ischaemic left ventricular dysfunction. Khoury, V. K., B. Haluska, et al. Heart (2003).**89**(1): 61-5

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12482794

High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Kinlay, S., G. G. Schwartz, et al. Circulation (2003).**108**(13): 1560-6

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12975259

Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. McDermott, M. M., J. M. Guralnik, et al. Circulation (2003).**107**(5): 757-61

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12578881

Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Mohler, E. R., 3rd, W. R. Hiatt, et al. Circulation (2003).**108**(12): 1481-6

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12952839

Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Montalescot, G., C. Bal-dit-Sollier, et al. Am J Cardiol (2003).**91**(8): 925-30

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12686329

Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Reffelmann, T. and R. A. Kloner. Circulation (2003).**108**(2): 239-44

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12860892

Effect of angiotensin-converting enzyme inhibition on restenosis after coronary stenting. Ribichini, F., W. Wijns, et al. *Am J Cardiol* (2003).**91**(2): 154-8

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12521626

Endothelin receptor blockers in cardiovascular disease. Rich, S. and V. V. McLaughlin. *Circulation* (2003).**108**(18): 2184-90

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14597580

Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation. Sack, M. N. and D. M. Yellon. *J Am Coll Cardiol* (2003).**41**(8): 1404-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12706939

Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Salonen, R. M., K. Nyssonen, et al. *Circulation* (2003).**107**(7): 947-53

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12600905

Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. van der Horst, I. C., F. Zijlstra, et al. *J Am Coll Cardiol* (2003).**42**(5): 784-91

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12957421

Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker. Wang, F. W., A. Osman, et al. *Circulation* (2003).**107**(23): 2914-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12771007

Nicorandil versus isosorbide dinitrate as adjunctive treatment to direct balloon angioplasty in acute myocardial infarction. Ikeda, N., T. Yasu, et al. *Heart* (2004).**90**(2): 181-5

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14729792